Trials / Withdrawn
WithdrawnNCT01245088
Chondroitin Sulfate for Crohn's Disease
A Pilot Study of Chondroitin Sulfate (CS) for the Treatment of Mild to Moderate Crohn's Disease
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University Hospitals Cleveland Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Pilot trial of open-label chondroitin sulfate 400 mg TID for adult patients with mild to moderate Crohn's disease. Primary endpoint with be evidence of bilogic effect assessed through serum and tissue cytokine analysis. Secondary endpoints are evidence of clinical effect, endoscopic healing, and histologic improvment. Trial duration is 8 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chondroitin sulfate | 400 mg orally three times daily for 8 weeks |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-03-01
- Completion
- 2012-05-01
- First posted
- 2010-11-22
- Last updated
- 2012-08-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01245088. Inclusion in this directory is not an endorsement.